Clinical Trial

8-OHdG and Oxidative Stress in Febrile Seizures

Completed
View on ClinicalTrials.gov →
Summary
This prospective case-control study investigates whether serum 8-hydroxy-2'-deoxyguanosine (8-OHdG), an established biomarker of reactive oxygen species-mediated DNA oxidation, is elevated in children with febrile seizures compared with healthy children, and whether it differs between simple and complex febrile seizure subtypes. Children presenting with a febrile seizure and age-matched healthy controls have serum 8-OHdG measured within 24 hours of seizure onset, alongside routine inflammatory markers (white-cell count, C-reactive protein) and haemoglobin. The primary aim is to determine whether acute oxidative DNA damage is detectable after febrile seizures and whether 8-OHdG levels distinguish simple from complex subtypes. The study is exploratory and hypothesis-generating; it is not designed to establish 8-OHdG as a clinically applicable diagnostic biomarker.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-16.
Trial Details
NCT Number NCT07660003
Lead Sponsor Kayseri City Hospital
Conditions Febrile Seizures, Oxidative Stress, Oxidative DNA Damage
Enrollment 156 participants
Start Date 2021-09-01
Primary Completion 2022-06-30 (estimated)
Study Completion 2022-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-07